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Introduction
Portal vein thrombosis (PVT) has a prevalence of
1% in the general population, and is mainly due to
liver cirrhosis and myeloproliferative diseases. Among
these, polycythemia vera (PV) and essential thrombo-
cythemia (ET) represent at least 25% of possible
causes of PVT.1,2 Moreover, myeloproliferative dis-
eases are the most important cause of Budd-Chiari
syndrome (50%), as well as of all other splanchnic
vein thrombosis (SVT). These are multifactorial dis-
eases that might be caused by liver cirrhosis, neo-
plasms, abdominal infections, phlogosis and genetic
or acquired abnormalities of coagulation pathway.2-4
We report 2 cases of young patients who were ad-
mitted to the Internal Medicine Department of the Gio-
vanni Paolo II Hospital, Sciacca (AG), Italy, due to the
sudden appearance of tense ascites and increase in
transaminase which we found to be affected by Budd-
Chiari syndrome as onset of an undiagnosed PV. We
also made a brief revision of international literature to
try to highlight the main etiopathogenetic and clinical
aspects of the disease, and the latest indications for a
correct therapeutic approach to these complex patients. 
Informed consent
Informed consent was obtained from both patients
for publication of their clinical cases.
Case Report #1
A 29-year old Egyptian man was admitted to our De-
partment due to sudden onset of abdominal pain and dis-
tension and diarrhea. Family and personal anamneses
were uneventful as was his past medical history. Physi-
cal examination showed tense and globular abdomen,
diffuse pain on superficial and deep palpation, abundant
ascites and peripheral edema; no other signs or symp-
toms could be found. He, therefore, underwent routine
hematochemical analysis that was normal except for mi-
crocytic hypochromic polycythemia, neutrophilic
leukocytosis, hypoalbuminemia and transaminases, and
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increase in cholestasis indexes and inflammatory mark-
ers (Table 1). He underwent thorax and abdominal X-
ray (which proved normal) and abdomen ultrasound
(US) scan which showed abundant ascites, liver with an
non-homogeneous echogenicity pattern, increased portal
vein diameter (1.64 cm) with few flow signs, and in-
creased spleen volume (longitudinal diameter 15.7 cm).
This profile was compatible with portal vein thrombosis.
For this, evacuative paracentesis was practised and 6 L
of yellow citrine ascites were removed. Physical-chem-
ical, microbiological and histological examination
proved negative for exudates or neoplasms (Table 2).
Broad-spectrum antibiotic therapy was started with
cephalosporins plus fluoroquinolones, as well as antico-
agulant therapy with low molecular weight heparin
(LMWH) and warfarin. LMWH was administered till
the international normalized ratio (INR) reached thera-
peutic values (range 2.5-3).
During the following days, despite therapy and al-
bumin administration, due to the abovementioned hy-
poalbuminemia, rapid ascite formation recurred for
which the patient underwent multiple evacuative para-
centesis (always finding yellow citrine ascites). More-
over, due to persistence of diarrhea, macroscopic,
physical-chemical, microbiological and parasitologi-
cal examinations of the stool were performed. All
proved negative so diarrhea was treated with sympto-
matic drugs (i.e. loperamide) with benefit.
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Table 1. Abnormal hematochemical parameters in Case #1. 
Admittance Discharge Reference values
Red blood cell count 6.74¥1012/L 5.84¥1012/L 4.5-6¥1012/L
Hemoglobin 17.2 g/dL 16.8 g/dL 13-17 g/dL
Hematocrit 53.9%, 52.9% 42-54%
Mean corpuscular volume 74.2 fL 76.6 fL 78-95 fL
Mean corpuscular hemoglobin 24.5 pg 24.9 pg 27.0-32.0 pg
AST 59 U/L 36 U/L 10-40 U/L
ALT 69 U/L 22 U/L 9-41 U/L
γ-GT 121 U/L 58 U/L 8-61 U/L
ALP 315 U/L 136 U/L 80-270 U/L
Total bilirubin 2.47 mg/dL 1.12 mg/dL 0.20-1.60 mg/dL
Albuminemia 2.5 g/dL 3.5 g/dL 3.48-5.39 g/dL
CRP 4.9 mg/L 2.4 mg/L 0-4 mg/L
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; CRP, C-reactive protein.
Table 2. Ascites physical-chemical characteristics.
Case #1 Case #2
Cell counts
White blood cells 0.12¥103/mL 0.17¥103/mL
Neutrophils 0.07¥103/mL 0.07¥103/mL
Lymphocytes 0.01¥103/mL 0.02¥103/mL
Monocytes <0.01¥103/mL <0.01¥103/mL
Chemical and physical examination
Color Yellow Yellow
Appearance Limpid Limpid
pH 7.8 7.7
Specific weight 1010 1008
Rivalta’s test Negative Negative
Nitrites Absent Absent
Total protein 12 g/L 20 g/L
Microscopy Negative Negative
Microbiology No growth No growth
Cytology Cytoatypia-free sediment Cytoatypia-free sediment
with some mesothelium cells with some mesothelium cells and rare lymphocytes
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Over the same days, glycated hemoglobin (HbA2)
quantification and coagulation screening (both within
normal limits), as well as d-dimer (significantly posi-
tive) and tumor marker evaluation (a-fetoprotein, CA
19.9, CA 15.3, and CEA, all negative) were per-
formed, and all routine tests were repeated. There was
a marked deterioration in liver and renal function, and
microcytic hypochromic polycythemia and neutrophi-
lic leukocytosis were confirmed. An abdominal com-
puterized tomography (CT) scan with intravenous
contrast was performed. This showed the presence of
abundant ascites, an increase in liver volume charac-
terized by non-homogeneous density, portal and
splenic vein non-visualization, such as thrombosis,
and splenomegaly, in absence of ischemic areas.
Some days later, the patient underwent another ab-
dominal US scan which confirmed the abovemen-
tioned findings with, however, in addition the
appearance of hepatic veins thrombosis (Budd-Chiari
syndrome) and suggesting a hepatic profile compatible
with liver stasis. This was confirmed by a further tho-
rax and abdomen CT with intravenous contrast, which
also showed the presence of small pleural effusion and
splenic and portal vein partial recanalization. At the
same time, we observed the contemporary and impres-
sive improvement in liver function and cholestasis
serological parameters, while red blood cell and white
blood cell count abnormalities remained unchanged.
Meanwhile, according to a differential diagnosis of
portal vein thrombosis, we evaluated blood markers of
major and minor hepatotropic viruses, human immun-
odeficiency virus (HIV) types 1 and 2, and throm-
bophilic disorders (lupus anticoagulant, anti-cardiolipin
antibodies, antinuclear antibodies HEp 2, native DNA
antibodies, plasma anticoagulant protein C, protein S,
and homocysteine). All were within normal range.
Given his Egyptian origin, schistosomiasis was excluded
by detection of serum anti-schistosome antibodies.
Due to the persistence of hypochromic microcytic
polycythemia and portal vein thrombosis (verified by
control abdominal US scan), we consulted a hematol-
ogy specialist. After excluding presence of atypical
lymphocyte subpopulations, the hematology specialist
performed a bone marrow biopsy with evidence of an
increase in erythroid and myeloid blast population.
Therefore, according to international guidelines
(Table 3), the patient underwent erythropoietin and
mutation JAK2 V617F assays; both tested positive. We
made a conclusive diagnosis of splenic, portal and he-
patic vein thrombosis caused by PV hyperaggregabil-
ity. We started combined therapy with oral
acetylsalicylic acid (100 mg/day) and oral hydrox-
yurea (15 mg bid). After the first three weeks of ther-
apy, there was a marked reduction in red blood cells
count, hemoglobin and hematocrit, up to a complete
normalization at four weeks (Table 1). Furthermore, a
consistent reduction in ascites was observed. Control
thorax and abdominal CT with intravenous contrast
was performed showing partial resolution of venous
thrombosis (almost complete for the portal vein, to al-
most nothing for hepatic outflow veins). The patient
continues periodic clinical, laboratory and imaging
follow up at the hematology clinic of our Institution.
Case Report #2
A 39-year old Sicilian woman was admitted to our
Department due to sudden onset of abdominal disten-
sion and dyspnea. Family and personal anamneses
were uneventful as was her past medical history with
the exception of hypertension (father) and diabetes
(grandmother). On physical examination, the ab-
domen appeared tense, globular, non-tender at super-
ficial and deep palpation, with probable ascites that
exceeded the transverse umbilical line of approxi-
mately 3 cm. Examination of other organs and systems
did not show anything relevant, excluding sinus tachy-
cardia confirmed by electrocardiography. Routine
blood tests showed pathological increase in transami-
nases, cholestasis and inflammation indexes. More-
over, the patient presented a clear microcytic
normochromic polycythemia profile (Table 4). Ac-
cording to the abovementioned clinical and laboratory
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Table 3. Proposed revised World Health Organization’s criteria for polycythemia vera. Diagnosis requires the presence
of both major criteria and 1 minor criterion or the presence of the first major criterion together with 2 minor criteria. 
Major criteria
1. Hemoglobin >18.5 g/dL in men, >16.5 g/dL in women, or other evidence of increased red cell volume*
2. Presence of JAK2 V617F or other functionally similar mutation such as JAK2 exon 12 mutation
Minor criteria
1. Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and
megakaryocytic proliferation
2. Serum erythropoietin level below the reference range for normal
3. Endogenous erythroid colony formation in vitro
*Hemoglobin or hematocrit greater than 99th percentile of method-specific reference range for age, gender, altitude of residence or hemoglobin greater than 17 g/dL in men, 15 g/dL
in women if associated with a documented and sustained increase of at least 2 g/dL from an individual’s baseline value that can not be attributed to correction of iron deficiency, or
elevated red cell mass greater than 25% above mean normal predicted value. Modified from Tefferi et al.,2007.5
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findings, the patient underwent evacuative paracente-
sis, with removal of 4 L of flaxen serous fluid (physi-
cal-chemical, microbiological and histological
examination proved negative for exudates or neo-
plasms) (Table 2). Abdominal CT (Figure 1) and mag-
netic resonance imaging (Figure 2) with intravenous
contrast were, therefore, performed and these showed
significant increase in liver volume with parenchymal
non-homogeneous density, such as liver cirrhosis, he-
patic veins, superior mesenteric vein, splenic vein and
spleen-mesenteric confluence failure, showing as in-
veterate thrombosis, vicarages by various collateral
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Table 4. Abnormal hematochemical parameters in Case #2.
Admittance Discharge Reference values
Red blood cell count 7.46¥1012/L 6.34¥1012/L 4.5-6¥1012/L
Hemoglobin 16.5 g/dL 15.9 g/dL 13-17 g/dL
Hematocrit 52.4% 51.2% 42-54%
Mean corpuscular volume 70.2 fL 75.8 fL 78-95 fL
Mean corpuscular hemoglobin 22.1 pg 22.7 pg 27.0-32.0 pg
AST 406 U/L 50 U/L 10-40 U/L
ALT 366 U/L 38 U/L 9-41 U/L
γ-GT 114 U/L 42 U/L 8-61 U/L
ALP 602 U/L 127 U/L 80-270 U/L
Total bilirubin 5.26 mg/dL 1.24 mg/dL 0.20-1.60 mg/dL
Albuminemia 3.0 g/dL 3.98 g/dL 3.48-5.39 g/dL
CRP 4.6 mg/L 1.0 mg/L 0-4 mg/L
AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma glutamyl transpeptidase; ALP, alkaline phosphatase; CRP, C-reactive protein.
Figure 1. Computed tomography with intravenous contrast
enhancement: increased liver volume, with heterogeneous
density characterized by patchy enhancement, hepatic
veins lack of opacification after intravenous administration
of contrast, splenomegaly and abundant ascites. 
Figure 2. Magnetic resonance imaging with intravenous
contrast enhancement: hepatomegaly with parenchymal in-
homogeneous density, abundant ascites, mild splenomegaly,
hepatic veins, superior mesenteric vein, splenic vein and
spleen-mesenteric confluence failure shown.
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circulation, presence of probable regenerative nodules
in S6 and S7, and a large amount of ascites. Further-
more, the patient underwent esophagogastroduo-
denoscopy that resulted normal except for a mild
hyperemia of the gastric fundus, and echocardiogra-
phy that was also normal.
Due to persistent polycythemia, persistence of mas-
sive ascites and evidence from imaging data, the patient
underwent evaluation of blood markers of hepatotropic
viruses, HIV types 1 and 2, and thrombophilic disorders
(lupus anticoagulant, anti-cardiolipin antibodies, anti-
nuclear antibodies HEp 2, native DNA antibodies,
plasma anticoagulant protein C, protein S, and homo-
cysteine) and of thyroid hormones. These were all
within normal limits. We therefore started combined
therapy with LMWH and oral anticoagulants until the
target INR range (INR 2.5-3.5) was achieved.
Given the strong suspicion of polycythemia vera,
genotyping for JAK2 V617F was tested and proved
positive. In accordance with all the collected data, the
patient was diagnosed with Budd-Chiari syndrome
due to PV, and combined therapy with oral acetylsal-
icylic acid (100 mg/day) and oral hydroxyurea (15 mg
bid) was started. The patient was discharged with a re-
markable improvement in her clinical and laboratory
condition (Table 4).
A subsequent abdominal CT control showed no
change from the previous radiological profile, and the
patient underwent transjugular intrahepatic portosys-
temic shunt (TIPS).
Currently the patient undergoes regular clinical
and laboratory follow up in our Department, without
further episodes of hepatic decompensation.
Discussion
Budd-Chiari syndrome can be defined as a hetero-
geneous group of disorders due to the obstruction, at
any level (hepatic venules, large hepatic veins, inferior
vena cava, right atrium), of the veins that guarantee
liver blood outflow.6
It is an extremely rare disease the incidence of
which is not well reported in literature, even if, re-
cently, Rajani et al. have reported an incidence of ap-
proximately 1 case per 1 million inhabitants. It usually
affects people between the fourth and fifth decade of
life, and no difference according to gender has been
reported. Mortality is highly variable, depending on
the onset; almost 90% in fulminant forms, remaining,
in the chronic forms, 55% at ten years from diagnosis.7
Pathogenesis may be attributable to a reduction in
outflow from the liver leading to hepatic sinusoids and
portal vein increased pressure, with a progressive sta-
sis tendency and consequent hypoxic damage, as well
as portal vein thrombosis.6,8 A further possible mech-
anism, related to blood stasis and hypoxic injury,
which can promote hepatocellular damage, could be
production of free radicals and the resulting oxidative
damage.6,9
The disease culminates in centrilobular necrosis
and, by well-known mechanisms of hepatic fibrosis
and nodular regeneration, onset of terminal cirrhosis.6
Budd-Chiari syndrome etiology is not unique. It
seems, in fact, that many factors, both acquired and
genetic, may contribute to it. In particular, all hyper-
coagulable conditions play a major role, and can be
identified in over 75% of all Budd-Chiari syndrome
cases.10,11 Among these are myeloproliferative dis-
eases. PV can be identified in 10-40% of all cases,
while ET in a slightly lower rate.6,12-14 Even more evi-
dence of the close relationship between Budd-Chiari
syndrome and myeloproliferative diseases, an expan-
sion of the endogenous erythroid-colony formation
units in bone marrow, as to underlie a misunderstood
myeloproliferative disease, can be observed in over
85% of patients in whom the etiology remains un-
known (idiopathic).6,12,13 All other possible causes of
Budd-Chiari syndrome and portal vein thrombosis, are
listed in Table 5.
Clinical onset of Budd-Chiari syndrome is ex-
tremely variable and largely depends on the hepatic
outflow vein occlusion speed. In fact, slow and pro-
gressive thrombosis ensures porto-systemic shunts
genesis, with consequent minor stasis and hepatocel-
lular damage. Vice versa it will result in a rapid occlu-
sion, and massive or sub-massive liver damage might
appear as fulminant and unexpected hepatic fail-
ure.11,15-17
Therefore, at least four forms of Budd-Chiari syn-
drome can be identified: fulminant, acute, subacute,
and chronic. Patients with fulminant Budd-Chiari syn-
drome usually present with jaundice associated with
an increase in liver function enzymes, nausea, vomit-
ing, abdominal pain, and, within eight weeks of the
onset, hepatic encephalopathy. In the acute form, there
is a tendency to rapid and progressive liver
parenchyma necrosis, with increase in transaminase,
though smaller than that of the fulminant forms, in as-
sociation with jaundice, pruritus, abdominal pain, and
intractable ascites appearance. The subacute forms are
certainly the most frequent, and their onset is insidious
because ascite and laboratory abnormalities typical of
hepatocellular damage are reduced, due to extensive
collateral porto-systemic shunt formation. Finally,
chronic Budd-Chiari syndrome is evident in patients
with previous history of liver cirrhosis, as possible
complication. Hepatomegaly is present in all four
forms, while splenomegaly and esophageal varices are
typical of subacute and chronic disease.6,15-17
Portal vein thrombosis and Budd-Chiari syndrome
etiology can be considered to overlap, even if their
clinical, laboratory and radiological profile might dif-
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fer. PVT usually involves the portal trunk extending,
generally, toward the mesenteric vein and splenic vein.
Its clinical onset may be acute or chronic. However,
in approximately 35% of all cases it could be totally
asymptomatic, only being confirmed after imaging.18
There is no agreement about the parameters needed
to distinguish acute from chronic forms. As a general
condition, a portal vein thrombosis whose symptoms
developed no more than 60 days before hospitalization
could be considered as acute.19,20 Acute thrombosis
might be totally asymptomatic or characterized by un-
specific bowel symptoms or signs (dyspepsia, abdom-
inal colicky pain, nausea and vomiting, and mild
abdominal distension) in most cases. However, severity
of symptoms and signs strictly depends on type (com-
plete or partial obstruction) and extension (portal, portal
and splenic, portal splenic and mesenteric, etc.) of
thrombosis. As a matter of fact, acute complete throm-
bosis extended to mesenteric vein could cause intestinal
ischemia, bowel infarction and ileus.19-21
Amitrano et al. reported major bleeding from
esophageal varices as possible acute PVT onset even
if they point out this could be due more to underlying,
still undiscovered cirrhosis rather than to acute onset
of portal vein thrombosis.18
In acute PVT, an inflammatory systemic response
is usually evidenced by acute inflammatory protein in-
crease (e.g. fibrinogens, C-reactive protein, erythro-
cyte sedimentation rate). Liver function enzymes are
within the normal range except for when an underly-
ing liver disease may be evidenced; this could be due
to an increase in arterial hepatic inflow to compensate
for venous inflow reduction.21
Infective portal vein thrombosis is characterized
by fever with chills, abdominal and liver pain, sud-
den onset of ascites, neutrophil leukocytosis, in-
crease in inflammation markers and, sometimes,
septic shock. In this framework, liver septic ab-
scesses are common and blood cultures are usually
positive for Bacteroides spp.21
Chronic portal vein thrombosis, also known as
portal cavernoma, is characterized by symptoms and
signs connected with the collateral circles, which arise
from the attempt to replace the portal circulation, cre-
ating links upstream and downstream of the stenosis,
bypassing, generally, the hepatic filter. Location, size
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Table 5. Budd-Chiari syndrome and portal vein thrombosis possible etiologies.
Hypercoagulable states
• Antiphospholipid syndrome 
• Antithrombin deficiency 
• Cancers
• Factor V Leiden mutation 
• Methylenetetrahydrofolate reductase mutation TT677
• Myeloproliferative disorder 
• Nephrotic syndrome 
• Oral contraceptives 
• Paroxysmal nocturnal hemoglobinuria 
• Polycythemia rubra vera 
• Pregnancy 
• Prothrombin mutation G20210A
• Protein C deficiency 
• Protein S deficiency 
• Sickle cell disease
Complications of therapeutic interventions
• Alcohol injection 
• Cholectomy 
• Endoscopic sclerotherapy 
• Fundoplication 
• Gastric banding 
• Hepatic chemoembolization 
• Hepatobiliary surgery 
• Islet cell injection 
• Liver transplantation 
• Peritoneal dialysis 
• Radiofrequency ablation of hepatic tumor(s) 
• Splenectomy 
• TIPS procedure 
• Umbilical vein catheterization
Infections
• Appendicitis
• Aspergillosis
• Cholangitis 
• Cholecystitis 
• Diverticulitis 
• Liver abscess 
• Schistosomiasis 
• Umbilical vein infection
Impaired portal vein flow
• Adrenal carcinoma 
• Cirrhosis 
• Cholangiocarcinoma 
• Hepatocellular carcinoma 
• Nodular regenerative hyperplasia 
• Pancreatic carcinoma 
• Renal cell carcinoma 
• Sinusoidal obstruction syndrome
Inflammatory diseases
• Behçet’s syndrome 
• Inflammatory bowel disease 
• Pancreatitis
Others
• Bladder cancer 
• Choledochal cyst
• Dacarbazine therapy 
• Living at high altitude
• Trauma
TIPS, transjugular intrahepatic portosystemic shunt. Modified from Menon et al., 2004.4
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and features of collateral circles vary: duodenal, antral,
pancreatic and biliary veins could be involved.
To date, chronic portal vein thrombosis diagnosis
has been mainly casual, due to ultrasonography stud-
ies often connected to other diseases or symptoms; so
asymptomatic onset of this disease is rare. Sometimes
jaundice, pruritus, fever, biliary pain, nausea and vom-
iting as well as cholangitis, cholecystitis and pancre-
atitis may signal onset of PVT. This condition is called
portal cholangiopathy and its pathophysiological ori-
gin lies in the compression of the common bile duct
by the collateral veins.
Variceal bleeding is not an unknown condition,
whereas ascites and hepatic encephalopathy are rare.21,22
The first imaging approach to both Budd-Chiari syn-
drome and portal vein thrombosis is ultrasonography.
In PVT, overdistension of portal vein could be found
associated with the presence of hyperechoic materials
inside of and disappearance of normal hepatic inflow.
However, early thrombosis may appear as hypoechoic,
causing a difficult detection, so a color Doppler imaging
should be always performed as well to evaluate disap-
pearance of normal hepatic flow.23,24
Ultrasonography in Budd-Chiari syndrome shows
enlarged liver with caudate lobe hypertrophy. Hepatic
veins could be partially or completely undetected.
Otherwise, intraluminal hyperechoic material or dila-
tation of proximal tract may be observed. Inferior vena
cava could be compressed by caudate lobe or show th-
rombus inside of it; rarely an aneurysmal dilatation
can be detected. Excluding paraumbilical vein, also
reported in portal vein thrombosis, appearance of in-
trahepatic collaterals is a specific sign of Budd-Chiari
syndrome.
Color Doppler imaging can show no or abnormal
direction flow in hepatic veins, whereas high-speed
flow can be detected at the site of stenosis. Ascites
may be detected easier in acute than in subacute or ch-
ronic Budd-Chiari syndrome. Both Budd-Chiari and
portal vein thrombosis, in acute or chronic stage, have
US measurable splenomegaly.24,25 CT scans in portal
vein thrombosis evidence well-defined intraluminal
filling defect with central low attenuation, collateral
circulation, engorgement of mesenteric veins, and me-
senteric edema. Ultrasonography and CT are both spe-
cific and sensitive imaging techniques: the first is less
invasive and provides a faster diagnosis and allows
closer follow up; the second is more accurate and bet-
ter identifies extension of thrombosis, especially
towards problematic ultrasonography areas (mesente-
ric veins).18,21,24
The CT profile of acute Budd-Chiari syndrome is
characterized by complete occlusion of hepatic veins
(hypoattenuating) with severe ascites, with low pe-
ripheral and major central hepatic contrast enhance-
ment. Splenomegaly is almost always evidenced, as
are ascites. Subacute and chronic CT Budd-Chiari pro-
files are usually less clear. A nuanced hypoperfusion
can be found in several hepatic parenchimal areas, to-
gether with collateral circulation and increase in di-
ameter of the hepatic artery. The typical cirrhosis
finding of regenerative nodules, with a diameter of
0.5-4 cm, is usually evidenced by both contrasted and
non-contrasted scans.24
In our Case #1, early onset of portal vein throm-
bosis which appears to have preceded the occlusion of
the hepatic veins, as well as what in our experience
has shown to be higher frequency of other hepatocel-
lular causes of injury delayed the diagnosis, requiring
the patient to undergo a number of evacuative para-
centeses and other invasive investigations, such as CT.
We should also mention that only 4-7% of patients af-
fected with polycythemia vera are under 40 years of
age, and, of these, only 2-10% will develop a Budd-
Chiari syndrome.26
Moreover, polycythemia vera is a far from com-
mon disease, occurring without differences of gender
or race, especially in individuals older than 60 years.
Annual incidence is highly variable, depending on the
studies, ranging from 0.2¥106 inhabitants/year in
Japan to 28¥106 inhabitants/year in Sweden.27-29 It is
already known that myeloproliferative diseases are
closely related to JAK2 V617F mutation, which can
be identified in over 95% of polycythemia vera cases
and over 60% of essential thrombocythemia and idio-
pathic myelofibrosis cases.30,31 In addition, several re-
cent studies pointed out that the presence of this
mutation could be found in almost 35% of all splanch-
nic vein thrombosis forms, and in 41-59% of patients
with Budd-Chiari syndrome.32,33 Association between
JAK2 mutation and the onset of splanchnic thrombosis
appears to be linked to the presence of morphological
and functional abnormalities of endothelial cells,
leukocytes and platelets. In particular, some cellular
receptors, such as CD11b, CD14, CD62P, CD63 and
P-selectin, seem to be over-expressed on the cytoplas-
mic membrane of these cells. Furthermore, P-selectin
has an important role in attracting and activating
leukocytes at the site of possible endothelial injury.
JAK2 mutation seems to be able to induce leukocyte-
platelet aggregates and activate the coagulation cas-
cade.34 Given this, the presence of other molecular
microaggregates, including CD11b/CD62P and
CD11b/CD42b, and of blood hyperviscosity, due to
the high number of red blood cells, seem to explain
the thrombophilic tendency of JAK2 positive patients,
beyond the presence or absence of a contemporary
myeloproliferative disease.34-36 Moreover, an increased
tissue factor synthesis by JAK2 positive macrophages
has been noticed in patients affected with SVT. So re-
cently JAK2 V617F mutation has been considered
among the possible diagnostic tools for the correct and
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early diagnosis of splanchnic vein thrombosis.34 Smal-
berg et al. recently demonstrated the importance of the
JAK2 mutations in splanchnic vein thrombosis. In 199
newly diagnosed patients, they noted that 46/1 JAK2
haplotype expression (indicating the presence of sin-
gle nucleotide polymorphism rs12343867) is signifi-
cantly over-expressed in patients with JAK2 V617F
mutation and splanchnic vein thrombosis compared to
controls [heterozygous odds ratio (OR) 2.1, homozy-
gous OR 4.1; P<0.01]. In patients who are JAK V617F
negative without myeloproliferative diseases and af-
fected with splanchnic vein thrombosis, the haplotype
46/1 does not appear to cause increased risk of
splanchnic vein thrombosis compared to controls (het-
erozygous OR 1.0, homozygous OR 1.1; P=0.98). Fi-
nally, in the JAK V617F negative patients with
myeloproliferative diseases and splanchnic vein
thrombosis, the risk of thrombosis seems significant
compared to controls only in the case of homozygous
mutation (heterozygous OR 0.6, homozygous OR 5.3;
P=0.6). The authors also emphasized that, in all JAK2
V617F mutation negative patients, haplotype 46/1 ex-
pression is, in any case, linked to an increased erythro-
poiesis. For these reasons they suggest adding the
search for this haplotype to the diagnostic tools of
splanchnic vein thrombosis diagnosis.31
A recent Italian study analyzed all the possible
causes of death in 192 patients with polycythemia
vera. The most important were found to be cardiovas-
cular complicacy (36.4%), including arterial thrombo-
sis (24%), venous thromboembolism (5.2%) and other
cardiovascular diseases (7.2%). These are signifi-
cantly higher than all other causes, including neo-
plasms (30%), hemorrhages (3.1%), polycythemia
evolution (2.6%, spent phase 2.1%, myelodysplasia
0.5%) and all other causes (28.1%, including hepatic
failure 2.1%).37 The same Italian study evaluated the
natural history of 1213 polycythemia vera treated pa-
tients, pointing out that the cumulative median sur-
vival exceeded 15 years, with overall mortality of 2.94
deaths/100 patients per year.40,41 Previous data evi-
denced a median survival of 18 months in untreated
patients, thus confirming the importance of an early
and correct treatment to drastically reduce complica-
tions, delay transformation into myeloid metaplasia
with myelofibrosis or acute myeloid leukemia, and in-
crease survival.38
Polycythemia vera treatment is largely dependent
on the age of the patient, risk of thrombosis and pro-
gressive development of thrombocytosis or
splenomegaly, indexes of disease evolution.38 The first
therapeutic approach is still phlebotomy to maintain
hematocrit consistently below 45%. The only random-
ized study that compared phlebotomy with myelosup-
pressive therapy is the PVSG-01trial that stressed that
the median survival in the study arm in which patients
underwent only phlebotomy was significantly greater
(13.9 years) than the arm undergoing therapy with
agents such as radiophosphorus (11.8 years) and chlo-
rambucil (8.3 years). This study, however, had great lim-
itations. First of all, a large number of enrolled patients
dropped out in the phlebotomy alone arm (50% at 5
years and 90% at 10 years) due to lack of compliance,
onset of complications or disease progression.38-41 So
far, the approach based exclusively on phlebotomies
is indicated only in patients at low risk of thrombosis
(age<60 years and no history of previous thrombotic
events).38 In those patients in whom phlebotomy alone
is not able to prevent complications, myelosuppressive
therapy should be started as soon as possible. In sub-
jects older than 70 years the use of radiophosphorus
and busulfan or other alkylating agents is strongly ad-
vised, in combination with aspirin if the patient is at
high thrombotic risk. Three randomized trials (PVSG-
01 trial, EORTC, FPSG) confirmed that these drugs
significantly reduce thrombosis risk and delay
myelofibrosis, indicating, also, that they should be
used only in elderly patients because of their high mu-
tagenicity.39,42-44 In all other patients (age<70 years),
cytoreductive therapy with hydroxyurea should be
considered. Many studies evaluated the efficacy and
safety of this drug, compared both to untreated pa-
tients and those treated with alkylating agents, under-
lining the significant reduction in thrombosis risk
(5.6% vs 21.6%) and increased survival.38,45 Neverthe-
less, many doubts remain about the proven leuke-
mogenicity and myelodysplastic potential of
hydroxyurea.38,46
In younger patients (age<60 years), the Nordic
MPD Group 2009 guidelines indicate using interferon
α as first-line therapy. This would act by suppressing
hematopoietic progenitor proliferation by a direct in-
hibitory effect on bone marrow progenitors and antag-
onizing platelet-derived growth factor and other
cytokines, as transforming growth factor-β. Moreover,
it seems not to have any teratogenic or leukemogenic
effect. So far, however, there have been no random-
ized studies of its efficacy and safety.47-49
Regarding anagrelide, a novel platelet-lowering
agent, the Nordic MPD Group guidelines reported its
use only and exclusively in thrombosis related to cases
of essential thrombocythemia.47,50,51 Antiplatelet ther-
apy should be undertaken in all patients at high risk
of thrombosis. Unfortunately, no blood chemistry pa-
rameter (platelet count, bleeding time, etc.) correlates
with thrombotic risk in polycythemia vera patients.
This explains why the beginning of antiplatelet ther-
apy is entrusted exclusively to clinical judgment. The
dose of aspirin (ASA) has been studied in several clin-
ical trials, showing that, despite a minimum bleeding
risk, administration of low-dose ASA is able to signif-
icantly reduce the risk of thrombosis.52,53
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In our Case #1, we met with initial diagnostic and
therapeutic difficulties due, mistakenly, to our previous
experience given the nationality of the patient, the low
incidence of this disease in young subjects and the ab-
normal presentation (portal vein thrombosis preceded
the Budd-Chiari syndrome). Initially, to reduce ascites,
we carried out several evacuative paracenteses simul-
taneously with anticoagulant therapy in an attempt to
stabilize the patient’s clinical condition and resolve the
portal vein thrombosis. Later, when the occlusion of
liver outflow veins was made explicit, contemporarily
with exclusion of other Budd-Chiari syndrome etiolo-
gies, we looked for and identified the underlying
myeloproliferative disease that was the basis of the dis-
order. To date, by continuous therapy with hydroxyurea
and low-dose ASA, the patient is in good health and
continues his clinical and laboratory follow up.
Case #2 experienced a partial failure in therapy,
for which reason the patient underwent TIPS. But
given our previous experience with the young Egypt-
ian patient, Case #2 was significantly simpler, both as
far as the diagnostic approach is concerned, and for
patient clinical management. We succeeded in a short
time to diagnose polycythemia vera and provide ade-
quate therapy.
Conclusions
We report 2 cases of Budd-Chiari syndrome in-
duced by a myeloproliferative disease (polycythemia
vera), characterized by an abnormal clinical onset, both
as regards subject’s age (29 and 39 years old, respec-
tively) and symptoms, signs and laboratory data (tense
ascites due to portal vein thrombosis, and red blood
cells and hematocrit values frankly not consistent with
polycythemia vera, especially in Case #1). Furthermore,
we would like to stress the importance of Case #1 for
our professional development, which allowed us to
achieve an early diagnosis of the disease in Case #2.
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